Sandu Pharmaceuticals Ltd.
Quick Take
- • Trading at 18.8× trailing earnings
- • Moderate ROE at 4.6%
- • Low leverage (D/E 0.01)
- • Attractive dividend yield of 2.72%
- • Operating margin 2.3% · Net margin 2.5%
- • Profit growth +60.90% YoY · Beta 0.39
Latest quarter · Jun 2026
| ₹ Cr | Jun 2026 | QoQ | YoY |
|---|---|---|---|
| Revenue | 16 | -5.88% | -5.88% |
| Operating Profit | 1 | +0.00% | +0.00% |
| Net Profit | 0 | — | — |
| EPS (₹) | 0.37 | +825.00% | +60.87% |
Shareholding Pattern
About the company
From latest AR & concallSandu Pharmaceuticals Limited manufactures and sells ayurvedic medicines under the SANDU brand in India and internationally. It offers immunity monsoon kit, sandu balm, sandu aptilift, sandu mahasudarshan kadha, sandu abhayarishta, sandu pathyadi kadha, sandu makarprash, sandu gulkand pravalyukta, sandu acivin herbal antacid, sandu ashwagandharishta, sandu amritarishta, sandu hemocleen excellent blood purifier, and sandu vanari granules. The company also provides mahasudarshan kadha, amritarishta, tab. samshamani vati, pathajeevani, vasa cough syrup, whoopin syrup, somajeevani, drakshasava, stressan, ashwagandharishtam, sandu sitopalasava, makarprash, chyavanprash, and ayush kwath. Its products are used for wellness, respiratory health, digestive health, and muscle and bone health. Sandu Pharmaceuticals Limited was founded in 1899 and is based in Mumbai, India.
